Michael Grant, MD, explores how clinicians can overcome real-world barriers to molecular testing in resected NSCLC.

Hello. This is Mark Kris, from Sloan Kettering, continuing my discussion about the increasing precision of lung cancer therapies and the need for additional testing beyond our routine next-generation ...

Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter ...

The Medicare coverage memo for next-generation DNA sequencing (NGS) was reopened to allow for NGS testing for other than late-stage cancers, but stakeholders are urging the U.S. Centers for Medicare ...

Claims-based uptake rose over time but remained discordant with biomarker-driven therapeutic paradigms, leaving most older adults potentially without actionable stratification at initial treatment ...

Please provide your email address to receive an email when new articles are posted on . Nearly half of people diagnosed with advanced cancer between 2018 and 2022 did not undergo next-generation ...

Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: A mono-institutional retrospective study.

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

Study shows iMDx test equivalent to NGS kits for dd-cfDNA measurement in kidney transplant patients, supporting future commercialization efforts. Results from a head-to-head comparison show iMDx's ...